To date, multiple LSD1 inhibitors have been developed for the treatment of hematologic malignancies and solid tumors, including RG6016, GSK-2879552, INCB059872, IMG-7289, CC-90011, SP-2509, and SP-2577 [42, 43], and a clinical trial investigating SP-2577 in relapsed Ewing sarcoma (NCT03600649) is currently recruiting patients. The gene discussed is KDM1A; the disease is Ewing sarcoma.